SCD-044 oral treatment for psoriasis starts phase 2

[Fred]

Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis.

Quote:

---

Sun Pharmaceutical today announced that it has initiated Phase 2 clinical trial for SCD-044 (a novel,orally bioavailable sphingosine-1-phosphate(S1P) receptor 1 agonist) in patients with moderate to severe plaque psoriasis.

The Phase 2 study is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SCD-044 in the treatment of moderate to severe plaque psoriasis.The study will enrol approximately 240 subjects and topline results are expected in 2022.

SCD-044 is a novel orally bioavailable S1P receptor 1 agonist for the treatment of inflammatory diseases such as atopic dermatitis and psoriasis. S1P receptor 1 agonists are promising for the treatment  of  autoimmune  inflammatory  diseases  as  they  cause  diminished  migration  of lymphocytes out of lymphatic tissue.

This results in a decrease of circulating lymphocytes, thereby reducing inflammation. A Phase 1 study of SCD-044 has been completed in healthy volunteers. This study established clinical  proof-of-concept  for  SCD-044in  terms  of  its safety  and pharmacodynamic  effects. Lymphocyte  count  reduction, a  surrogate  marker  of  efficacy forS1P receptor 1 agonists, was observed at all dose levels evaluated.

Source: sunpharma.com